Eli Lilly Reports 39% Revenue Increase and Strong Growth Strategy in Q3
Eli Lilly's Q3 report reveals a 39% revenue surge, driven by GLP-1 drugs. Learn about their strategic plans and market impact.
Washington Court Considers Health Insurer Coverage for Weight Loss Drugs
Explore the Washington Court's decision on health insurer coverage for weight loss medications, implications for patients, and the ongoing legal debate.
GLP-1 Receptor Agonists: A Breakthrough in Cardiovascular Health
Discover the breakthrough role of GLP-1 receptor agonists in cardiovascular health, FDA-approved for patients managing diabetes and obesity.
CMS Grants NTAP for Renata Medical's Pediatric Minima Stent System
CMS approves New Technology Add-on Payment for Renata Medical's Minima stent, enabling enhanced reimbursement for innovative pediatric congenital heart disease treatment.